Coronavirus - Covid 19 Information Sharing Forum Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Coronavirus - Covid 19 Information Sharing Forum

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: maceng2 who wrote (2873)	2/15/2022 5:07:26 AM
From: maceng2	2 Recommendations Recommended By FJB Thomas M. Read Replies (1) of 5935

Pfizer drops India vaccine application after regulator seeks local trial Pfizer drops India vaccine application after regulator seeks local trial \| Article [AMP] \| Reuters Krishna N. Das A vial and sryinge are seen in front of a displayed Pfizer and Biontech logo in this illustration taken January 11, 2021. REUTERS/DADO RUVIC/ILLUSTRATION/FILE PHOTO NEW DELHI (Reuters) - Pfizer Inc said on Friday it had withdrawn an application for emergency-use authorisation of its COVID-19 vaccine in India, after failing to meet the drug regulator's demand for a local safety and immunogenicity study. The decision means the vaccine will not be available for sale in the world's two most populous countries, India and China, in the near future. Both countries are running their immunisation campaigns using other products. Unlike other companies conducting small studies in India for foreign-developed vaccines, Pfizer had sought an exception citing approvals it had received elsewhere based on trials done in countries such as the United States and Germany. ADVERTISEMENT Indian health officials say they generally ask for so-called bridging trials to determine if a vaccine is safe and generates an immune response in its citizens. There are, however, provisions under India's rules to waive such trials in certain conditions. The U.S. company, which was the first drugmaker to seek emergency approval in India for its vaccine developed with Germany's BioNTech, made the withdrawal decision after a meeting with India's Central Drugs Standard Control Organisation (CDSCO) on Wednesday. The drug regulator said on its website its experts did not recommend the vaccine because of side effects reported abroad were still being investigated. It also said Pfizer had not proposed any plan to generate safety and immunogenicity data in India. "Based on the deliberations at the meeting and our understanding of additional information that the regulator may need, the company has decided to withdraw its application at this time," Pfizer said in a statement. "Pfizer will continue to engage with the authority and re-submit its approval request with additional information as it becomes available in the near future." Reuters was the first to break the news.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next